# STK-012

Source: https://onco.cc/drugs/stk-012/  
OnCo record `stk-012` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

STK-012 is an experimental engineered immune-signalling protein from Synthekine, in phase 2 trials for non-small cell lung cancer.

## Summary

STK-012 is an engineered cytokine (interleukin-2 partial agonist) from Synthekine. An alpha/beta-biased interleukin-2 partial agonist that preferentially stimulates antigen-activated T cells carrying the high-affinity IL-2 receptor, which includes CD25 (IL-2 receptor alpha) and IL2RB. The phase 2 part of NCT05098132 is in first-line PD-L1-negative non-squamous non-small cell lung cancer, with pembrolizumab, pemetrexed and carboplatin.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Code: STK-012
- Modality: Engineered cytokine (interleukin-2 partial agonist)
- Mechanism: An alpha/beta-biased interleukin-2 partial agonist that preferentially stimulates antigen-activated T cells carrying the high-affinity IL-2 receptor, which includes CD25 (IL-2 receptor alpha) and IL2RB.

## Sources

- Synthekine pipeline: https://www.synthekine.com/our-pipeline/
- ClinicalTrials.gov NCT05098132: https://clinicaltrials.gov/study/NCT05098132

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [CD25 (IL-2 receptor alpha)](https://onco.cc/targets/cd25/), [IL2RB](https://onco.cc/targets/il2rb/)
- companies: [Synthekine](https://onco.cc/companies/synthekine/)
- trials: [Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers](https://onco.cc/trials/nct05098132/)

---
JSON: https://onco.cc/api/v1/entities/stk-012.json